• Therapeutics >

Cell Lines For Angiogenesis Screening

Background:
The National Cancer Institute's Angiogenesis Core Facility is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize multicolored fluorescent cell lines and software for high-throughput screening of compounds that regulate angiogenesis and cytotoxicity.

Angiogenesis is fundamentally important in tissue development, vascular disease, and cancer progression.  The availability of high-throughput, simple assays for the study of multiple-cell biological processes, such as angiogenesis, is essential for the development of therapeutics and diagnostics for disorders governed by these complex processes.

Technology:
NCI researchers have developed a series of immortalized cell lines, selected to represent the different cell types found in in vivo angiogenesis, that constitutively express different fluorescent proteins.  Based on these cell lines, the researchers have developed several in vitro angiogenesis assays and a software application that can be used to investigate the relationships between different cells involved in angiogenesis.  This technology can be used to develop new combinatorial approaches to boost the efficiency of existing therapeutics and to facilitate the discovery of new potential single or combination drugs.

Value Proposition:

• Potential to develop a high-throughput screening assay for angiogenesis or anti-angiogenesis drugs, and to screen compounds for cytotoxicity;

• No added detection reagents to disrupt assay results;

• Ability to increase efficiency of existing therapeutics and to facilitate the discovery of new drugs;

• Ability to conduct real-time monitoring of cellular interaction and activity faster and more efficiently.

• Ability to study cell-cell interaction and screen drugs in complex 2D and 3D in vitro assays.

• Ability to easily track and study multicellular systems in in vivo models (including response to drug treatment).

• Development of additional cells lines representing other anatomical origins;

• Ectopic expression of additional fluorescent proteins and/or reporter systems.

• Further development to include the cells in a kit form to facilitate delivery and usability.

This opportunity is also listed under the following categories:

• Diagnostics